Nwam LLC Sells 52,670 Shares of CRISPR Therapeutics AG $CRSP

Nwam LLC lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 85.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,173 shares of the company’s stock after selling 52,670 shares during the quarter. Nwam LLC’s holdings in CRISPR Therapeutics were worth $436,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of CRSP. Mcguire Capital Advisors Inc. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $26,000. Rothschild Investment LLC raised its stake in CRISPR Therapeutics by 836.7% in the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after acquiring an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its stake in CRISPR Therapeutics by 196.9% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after acquiring an additional 382 shares during the period. Finally, Oakworth Capital Inc. acquired a new stake in CRISPR Therapeutics during the 4th quarter valued at $34,000. Institutional investors own 69.20% of the company’s stock.

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the transaction, the insider directly owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on CRSP. Citizens Jmp reaffirmed a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, July 6th. Sanford C. Bernstein raised their target price on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Monday, April 20th. Finally, Wall Street Zen lowered shares of CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $67.78.

CRISPR Therapeutics Stock Performance

CRSP opened at $47.78 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96. The business has a fifty day simple moving average of $53.10 and a 200 day simple moving average of $52.93. CRISPR Therapeutics AG has a 1 year low of $44.12 and a 1 year high of $78.48. The company has a market capitalization of $4.61 billion, a PE ratio of -7.68 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The firm had revenue of $1.46 million for the quarter. Research analysts expect that CRISPR Therapeutics AG will post -4.9 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.